Phase 2 data in adults with atopic dermatitis showed that all three zumilokibart dose regimens met the primary endpoint, with significantly greater improvements in Eczema Area and Severity Index -75 (EASI-75) response rates versus placebo at Week 16 1 The mid-dose regimen was selected for...
Hence then, the article about abbvie highlights positive results from the phase 2 apex part b study of zumilokibart in moderate to severe atopic dermatitis as a late breaker at eadv 2026 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026 )
Also on site :
- Feds Say AI Music Fraudster Deserves Prison For Stealing Royalties From ‘Hard-Working Songwriters’
- Robinhood just rolled out trading agents to millions—and investing may never be the same
- R.J. Decker's Real Killer Unpacks The Big Reveal: 'It Was Me, I Did It!' Plus, Have We Seen The Last Of [Spoiler]?